I agree about the buyout but it has to be at one hell of a price premium or I would be against it. I mentioned selling European rights to Carfilzomib because I don't think Onxx is so dumb as to not entertain offers that will give them a large cash infusion, and favorable revenues without having them expend significant outlays to sell Carfilzomib in both the US and Europe.
Market Data 
Markets 
AI
